PriceTargets.com logo

Sight Sciences - SGHT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $5.12
  • Forecasted Upside: 43.42%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 5 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
$3.57 As of 12/20/2024 06:16 PM ET
▲ +0.21 (6.25%)

This chart shows the closing price for SGHT by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sight Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SGHT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SGHT

Analyst Price Target is $5.12
▲ +43.42% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Sight Sciences in the last 3 months. The average price target is $5.12, with a high forecast of $5.50 and a low forecast of $4.60. The average price target represents a 43.42% upside from the last price of $3.57.

This chart shows the closing price for SGHT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 6 contributing investment analysts is to hold stock in Sight Sciences. This rating has held steady since July 2023, when it changed from a Moderate Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 1 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 1 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 4 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 5 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/11/2024CitigroupLower TargetNeutral ➝ Neutral$5.80 ➝ $4.60
12/6/2024UBS GroupInitiated CoverageBuy$5.50
11/11/2024Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$7.00 ➝ $5.00
11/8/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$6.00 ➝ $5.50
11/8/2024Needham & Company LLCReiterated RatingHold
11/4/2024Lake Street CapitalDowngradeBuy ➝ Hold$10.00 ➝ $5.00
8/21/2024Lake Street CapitalInitiated CoverageBuy$10.00
8/2/2024Needham & Company LLCReiterated RatingHold
7/15/2024Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$5.40 ➝ $6.50
7/10/2024CitigroupBoost TargetNeutral ➝ Neutral$6.00 ➝ $6.50
5/3/2024Piper SandlerReiterated RatingNeutral ➝ Neutral$5.00 ➝ $6.00
5/3/2024Needham & Company LLCReiterated RatingHold
4/10/2024Needham & Company LLCReiterated RatingHold
12/4/2023Morgan StanleyBoost TargetEqual Weight ➝ Equal Weight$3.00 ➝ $4.00
11/8/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$4.00 ➝ $3.00
9/18/2023Stifel NicolausLower TargetBuy ➝ Buy$11.00 ➝ $5.00
9/15/2023CitigroupLower TargetNeutral ➝ Neutral$8.00 ➝ $4.00
9/13/2023Morgan StanleyLower TargetEqual Weight ➝ Equal Weight$8.40 ➝ $4.00
9/12/2023Bank of AmericaDowngradeNeutral ➝ Underperform$10.00 ➝ $4.50
9/12/2023William BlairDowngradeOutperform ➝ Market Perform
9/11/2023Piper SandlerDowngradeOverweight ➝ Neutral$15.00 ➝ $5.50
8/24/2023Morgan StanleyDowngradeOverweight ➝ Equal Weight$12.00 ➝ $8.40
8/21/2023CitigroupLower TargetNeutral ➝ Neutral$9.00 ➝ $8.00
8/4/2023Morgan StanleyLower TargetOverweight ➝ Overweight$15.00 ➝ $12.00
7/10/2023CitigroupDowngradeBuy ➝ Neutral$15.00 ➝ $9.00
6/26/2023Stifel NicolausLower Target$15.00 ➝ $13.00
6/6/2023Bank of AmericaLower Target$13.00 ➝ $10.00
1/6/2023Morgan StanleyBoost TargetOverweight$11.00 ➝ $15.00
1/6/2023Stifel NicolausUpgradeHold ➝ Buy$10.00 ➝ $15.00
12/12/2022CitigroupBoost TargetBuy$10.00 ➝ $15.00
11/16/2022CitigroupBoost Target$10.00
11/11/2022Morgan StanleyBoost TargetOverweight$10.00 ➝ $11.00
11/10/2022William BlairReiterated RatingOutperform
10/11/2022Morgan StanleyLower TargetOverweight$14.00 ➝ $10.00
10/11/2022Bank of AmericaInitiated CoverageNeutral ➝ Neutral
10/5/2022CitigroupLower Target$13.00 ➝ $9.00
10/4/2022Needham & Company LLCInitiated CoverageHold
8/12/2022Piper SandlerLower TargetOverweight$17.00 ➝ $15.00
8/12/2022Morgan StanleyLower TargetOverweight$17.00 ➝ $14.00
7/26/2022Stifel NicolausReiterated RatingInitiates
7/25/2022Stifel NicolausInitiated CoverageHold$10.00
7/15/2022Morgan StanleyLower TargetOverweight$18.00 ➝ $17.00
5/11/2022Piper SandlerLower Target$23.00 ➝ $17.00
3/25/2022CitigroupLower TargetBuy$39.00 ➝ $35.00
3/25/2022Piper SandlerLower Target$43.00 ➝ $23.00
2/3/2022William BlairInitiated CoverageOutperform
1/7/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$36.00 ➝ $27.00
8/9/2021Bank of AmericaInitiated CoverageBuy$45.00
8/9/2021CitigroupInitiated CoverageBuy$46.00
8/9/2021Piper SandlerInitiated CoverageOverweight$44.00
8/9/2021Morgan StanleyInitiated CoverageEqual Weight$41.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

0.78 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 4 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 4 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 2 very positive mentions
  • 11 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
8/23/2024
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 3 very positive mentions
  • 9 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 6 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

Sight Sciences logo
Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. It also offers TearCare System, a wearable eyelid technology for adult patients with evaporative dry eye disease due to meibomian gland dysfunction, as well as related components. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. Sight Sciences, Inc. was incorporated in 2010 and is headquartered in Menlo Park, California.
Read More

Today's Range

Now: $3.57
Low: $3.30
High: $3.64

50 Day Range

MA: $4.43
Low: $3.36
High: $6.18

52 Week Range

Now: $3.57
Low: $3.12
High: $8.45

Volume

470,053 shs

Average Volume

203,060 shs

Market Capitalization

$181.20 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.58

Frequently Asked Questions

What sell-side analysts currently cover shares of Sight Sciences?

The following equities research analysts have issued reports on Sight Sciences in the last twelve months: Citigroup Inc., Lake Street Capital, Morgan Stanley, Needham & Company LLC, Piper Sandler, and UBS Group AG.
View the latest analyst ratings for SGHT.

What is the current price target for Sight Sciences?

0 Wall Street analysts have set twelve-month price targets for Sight Sciences in the last year. Their average twelve-month price target is $5.12, suggesting a possible upside of 43.4%. UBS Group AG has the highest price target set, predicting SGHT will reach $5.50 in the next twelve months. Citigroup Inc. has the lowest price target set, forecasting a price of $4.60 for Sight Sciences in the next year.
View the latest price targets for SGHT.

What is the current consensus analyst rating for Sight Sciences?

Sight Sciences currently has 5 hold ratings and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in SGHT, but not buy more shares or sell existing shares.
View the latest ratings for SGHT.

What other companies compete with Sight Sciences?

Other companies that are similar to Sight Sciences include Iradimed, AxoGen, Semler Scientific, SI-BONE and OrthoPediatrics. Learn More about companies similar to Sight Sciences.

How do I contact Sight Sciences' investor relations team?

Sight Sciences' physical mailing address is 4040 CAMPBELL AVE SUITE 100, MENLO PARK CA, 94025. The company's listed phone number is 877-266-1144 and its investor relations email address is [email protected]. The official website for Sight Sciences is www.sightsciences.com. Learn More about contacing Sight Sciences investor relations.